Disclosures for "Probable Cerebral Amyloid Angiopathy in Alzheimer’s Disease: Prevalence and Limited Clinical Impact in a Biomarker-defined Memory Clinic Cohort"
-
Mr. Lalive has nothing to disclose.
-
Dr. Ribaldi has nothing to disclose.
-
Mr. Mendes has nothing to disclose.
-
Mrs. Wang has received personal compensation for serving as an employee of Abbvie. Mrs. Wang has stock in Abbvie.
-
Dr. Chicherio has nothing to disclose.
-
Prof. Piazza has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Prof. Piazza has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Prof. Piazza has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Araclon. The institution of Prof. Piazza has received research support from Alzheimer's Association. The institution of Prof. Piazza has received research support from EU funds, PNNR .
-
Dr. Kern has nothing to disclose.
-
Dr. Boccalini has nothing to disclose.
-
Miss Harput has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Scheffler has nothing to disclose.
-
Prof. Lovblad has nothing to disclose.
-
Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk. The institution of Dr. Frisoni has received research support from Novo Nordisk.
-
The institution of Dr. Lathuiliere has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. The institution of Dr. Lathuiliere has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Release Therapeutics. The institution of Dr. Lathuiliere has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. The institution of Dr. Lathuiliere has received research support from Swiss National Science Foundation. The institution of Dr. Lathuiliere has received research support from Synapsis Foundation.